Cidofovir: Antiviral Treatment for Viral Skin Infections

Cidofovir: An Overview

Cidofovir is a potent antiviral medication originally developed and approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) infection. The drug, manufactured by Gilead Sciences in California, has emerged as an effective therapeutic option for various viral skin conditions beyond its initial indication. In recent years, dermatologists have increasingly utilized cidofovir for managing refractory viral skin diseases, particularly when conventional treatments have failed.

Mechanism of Action

Cidofovir functions as a nucleotide analog that inhibits viral DNA polymerase, the enzyme responsible for viral DNA replication in infected cells. By blocking this critical enzyme, cidofovir prevents the propagation of viral genetic material, effectively halting the growth and spread of viral infections. This mechanism makes cidofovir effective against a broad spectrum of DNA viruses, including human papillomavirus (HPV), which causes cutaneous warts, and other dermatotropic viruses.

Approved Indications and Off-Label Uses

While cidofovir’s primary FDA-approved indication remains CMV retinitis in immunocompromised patients, several small studies and case reports document successful off-label applications in dermatology. These applications include:

• Cutaneous viral warts — including plantar, periungual, and common warts resistant to conventional therapies
• Molluscum contagiosum — particularly generalized and facial lesions in immunocompromised individuals
• Acyclovir-resistant herpes simplex virus infections
• BK virus infections
• Adenovirus infections
• Recurrent respiratory papillomatosis

Routes of Administration

Cidofovir can be administered through multiple routes depending on the clinical indication and treatment goals. The three primary administration methods include:

• Intravenous administration — typically reserved for systemic infections such as CMV retinitis
• Topical application — applied directly to skin lesions as a cream or compounded formulation
• Intralesional injection — administered directly into individual lesions for localized viral infections

Topical Cidofovir for Skin Lesions

Application and Dosage

For topical treatment of viral skin conditions, cidofovir is typically applied at a concentration of 1% to 3% depending on the specific condition and patient tolerance. The standard recommended protocol involves:

• Concentration: 1% cream formulation for most wart indications; 3% for molluscum contagiosum
• Frequency: Applied daily, five days per week
• Duration: Eight weeks per treatment cycle
• Occlusion: Treatment areas should be covered with occlusive dressing to enhance medication penetration

Preparation and Application Technique

Cidofovir lacks a commercially available topical formulation and must be compounded by a pharmacy into a cream base. Before application, proper preparation of the lesion site is essential for optimal efficacy:

• Gently debride the wart to remove thickened skin and debris
• Protect surrounding healthy skin with petroleum jelly to prevent irritation and irritant dermatitis
• Apply cidofovir only to the target lesion using a cotton-tipped applicator or gloved finger
• Cover the treated area with an occlusive dressing for at least 12 hours to maximize penetration

Clinical Efficacy in Viral Warts

Research has demonstrated that topical cidofovir exhibits efficacy against various types of refractory warts. Published evidence supports its use for:

• Plantar warts — successfully treated in multiple case series
• Periungual warts — lesions around nail structures that are notoriously difficult to treat
• Common and facial verrucae — particularly in pediatric and immunocompromised populations

Treatment cycles may be repeated after a 1-2 week interval, with most patients requiring two to four treatment cycles for optimal results and complete resolution.

Molluscum Contagiosum Management

Cidofovir has demonstrated remarkable efficacy in treating recalcitrant molluscum contagiosum, especially in immunocompromised individuals. In a landmark case series, two children with AIDS and extensive molluscum contagiosum that had failed multiple conventional treatments—including liquid nitrogen, cantharidin, and tretinoin—were successfully treated with topical 3% cidofovir.

Treatment Protocol for Molluscum Contagiosum

The protocol employed in documented cases involved:

• Topical 3% cidofovir compounded in a specialized vehicle (Dermovan)
• Once-daily application, five days per week
• Eight weeks of continuous treatment
• Occlusion with adhesive tape for nonfacial lesions (minimum 12 hours)
• Avoidance of treatment near eyelids to prevent conjunctival irritation

In the documented cases, all treated lesions showed complete clinical resolution after two months of therapy. Lesions healed with superficial scarring and postinflammatory changes, which is superior to scarring patterns observed with more invasive treatments.

Safety Profile and Adverse Effects

Local Side Effects

Topical cidofovir is generally well-tolerated, with local irritation being the predominant adverse effect. Common local reactions include:

• Erythema and redness — typically appearing 5-15 days after initial application
• Painful erosions — at treatment sites, usually resolving during two-day rest periods
• Inflammation — localized to treated lesions with minimal perilesional involvement
• Postinflammatory hyperpigmentation and hypopigmentation — may occur after lesion resolution
• Burning sensation — at the application site during treatment
• Transient alopecia — reported in some cases with scalp involvement

Systemic Safety Considerations

The primary advantage of topical cidofovir over systemic administration is the avoidance of significant renal toxicity. When applied topically, systemic absorption is minimal, eliminating the nephrotoxicity concerns associated with intravenous therapy. Clinical monitoring in documented cases revealed:

• No development of neutropenia during treatment
• Normal serum urea nitrogen levels
• Normal creatinine levels within the physiological range
• Absence of systemic adverse effects in immunocompromised populations

However, one documented case reported acute renal function deterioration in a patient with preexisting chronic renal failure, suggesting that patients with baseline renal impairment require careful monitoring.

Comparison with Alternative Treatments

Cost Considerations and Accessibility

While topical cidofovir demonstrates significant therapeutic potential, accessibility remains limited in clinical practice. The primary barriers to widespread utilization include:

• High cost — cidofovir is an expensive antiviral medication, making treatment financially burdensome for many patients
• Lack of FDA approval — for dermatological indications limits insurance coverage and standardized prescribing
• Compounding requirements — absence of commercial topical formulations necessitates pharmacy compounding, adding cost and delay
• Limited clinical trial data — absence of large-scale randomized controlled trials restricts adoption by many practitioners

Despite these barriers, cidofovir represents a cost-effective alternative compared to surgical intervention or repeated office-based treatments for refractory warts.

Special Populations

Immunocompromised Patients

Cidofovir has proven particularly valuable for immunocompromised individuals, including those with HIV/AIDS and other immunosuppressive conditions. These patients often experience severe, widespread viral skin infections that resist conventional therapies. Topical cidofovir avoids the renal toxicity of intravenous therapy while effectively treating extensive lesions that cause significant physical and psychological burden.

Pediatric Patients

Case reports document successful cidofovir use in pediatric populations, including a 12-year-old child with Wiskott-Aldrich syndrome who had extensive molluscum contagiosum covering more than 75% of body surface area. Within 2-3 weeks of topical cidofovir therapy, acute inflammation was followed by lesion resolution, demonstrating efficacy and tolerability in children.

Treatment Considerations and Monitoring

Successful cidofovir therapy requires careful patient selection and monitoring. Key considerations include:

• Baseline renal function assessment — particularly important in patients with diabetes, hypertension, or preexisting renal disease
• Patient counseling — preparation for expected local reactions including erythema and erosion
• Regular monitoring — assessment at each visit for excessive irritation or systemic symptoms
• Skin barrier protection — use of emollients and barrier creams to minimize irritation
• Treatment adherence — compliance with the five-days-per-week regimen for optimal outcomes

Future Directions and Research Needs

While cidofovir demonstrates promise for managing refractory viral skin infections, several areas require further investigation:

• Double-blind controlled trials — to establish efficacy and safety compared to standard therapies
• Formulation optimization — development of commercial topical preparations to improve accessibility
• Comparative effectiveness studies — evaluation against emerging therapies and combinations
• Long-term follow-up data — assessment of recurrence rates and durability of response
• Mechanism-based research — investigation of viral resistance development and optimization strategies

Frequently Asked Questions

Q: Is topical cidofovir FDA-approved for treating warts?

A: No, cidofovir is FDA-approved only for CMV retinitis in AIDS patients. Its use for viral warts represents off-label therapy, though supported by published case reports and small studies.

Q: How long does cidofovir treatment typically take to show results?

A: Initial clinical response often appears within 5-15 days with redness and erosion at treatment sites. Complete resolution typically occurs after 8 weeks of continuous therapy, with some patients requiring multiple treatment cycles.

Q: Can topical cidofovir cause systemic side effects?

A: When applied topically, cidofovir has minimal systemic absorption and generally does not cause nephrotoxicity associated with intravenous administration. However, patients with preexisting renal impairment require careful monitoring.

Q: How does cidofovir compare to cryotherapy?

A: Cidofovir may cause less scarring than cryotherapy and is particularly useful for extensive or refractory lesions. However, cryotherapy is more readily available and requires fewer applications.

Q: Is cidofovir suitable for treating molluscum contagiosum in children?

A: Yes, case reports demonstrate successful treatment of extensive molluscum contagiosum in pediatric patients with AIDS and immunodeficiency syndromes, with good tolerability and minimal systemic effects.

Q: What precautions should be taken when applying topical cidofovir?

A: Protect surrounding healthy skin with petroleum jelly, avoid treatment near the eyes to prevent conjunctival irritation, debride lesions gently before application, and use occlusive dressing to enhance penetration.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

Sneha TeteBeauty & Lifestyle Writer

 

Sneha is a relationships and lifestyle writer with a strong foundation in applied linguistics and certified training in relationship coaching. She brings over five years of writing experience to renewcure,  crafting thoughtful, research-driven content that empowers readers to build healthier relationships, boost emotional well-being, and embrace holistic living.

Read full bio of Sneha Tete